Evidence map›Paper›PMID 27998022›Full record

ArticleJournal of cellular and molecular medicine2017

The effects of the DNA methyltranfserases inhibitor 5-Azacitidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells.

Katarzyna Kornicka, Krzysztof Marycz, Monika Marędziak, Krzysztof A Tomaszewski, Jakub Nicpoń

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Katarzyna KornickaFaculty of Biology, University of Environmental and Life Sciences, Wrocław, Poland.
Krzysztof MaryczFaculty of Biology, University of Environmental and Life Sciences, Wrocław, Poland.
Monika MarędziakFaculty of Veterinary Medicine, University of Environmental and Life Sciences, Wrocław, Poland.
Krzysztof A TomaszewskiDepartment of Anatomy, Jagiellonian University Medical College, Krakow, Poland.
Jakub NicpońDepartment of Surgery, Faculty of Veterinary Medicine, University of Environmental and Life Sciences Wroclaw, Wroclaw, Poland.
Wroclaw University of Environmental and Life Sciences · PLJagiellonian University · PLWroclaw Research Centre EIT+ (Poland) · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human adipose tissue is a great source of adult mesenchymal stem cells (MSCs) which are recognized from their ability to self-renew and differentiation into multiple lineages. MSCs have promised a vast therapeutic potential in treatment many diseases including tissue injury and immune disorders. However, their regenerative potential profoundly depends on patients' age. Age-related deterioration of MSC is associated with cellular senescence mainly caused by increased DNA methylation status, accumulation of oxidative stress factors and mitochondria dysfunction. We found that DNA methyltransferase (DNMT) inhibitor i.e. 5-Azacytidine (5-AZA) reversed the aged phenotype of MSCs. Proliferation rate of cells cultured with 5-AZA was increased while the accumulation of oxidative stress factors and DNA methylation status were decreased. Simultaneously the mRNA levels of TET proteins involved in demethylation process were elevated in those cells. Moreover, cells treated with 5-AZA displayed reduced reactive oxygen species (ROS) accumulation, ameliorated superoxide dismutase activity and increased BCL-2/BAX ratio in comparison to control group. Our results indicates that, treating MSCs with 5-AZA can be justified therapeutic intervention, that can slow-down and even reverse aged- related degenerative changes in those cells.

Indexed as

Adipose TissueAgedAntigens, SurfaceAzacitidinebcl-2-Associated X ProteinCell ProliferationCellular SenescenceClone CellsCulture MediaCyclin-Dependent Kinase Inhibitor p21DNA (Cytosine-5-)-MethyltransferasesDNA MethylationEnzyme InhibitorsFemaleFlow CytometryHumansAntigens, SurfaceAzacitidinebcl-2-Associated X ProteinCulture MediaCyclin-Dependent Kinase Inhibitor p21DNA (Cytosine-5-)-MethyltransferasesEnzyme InhibitorsKi-67 AntigenRNA, MessengerTumor Suppressor Protein p535-Azacitidineageingmesenchymal stem cellsmethylationoxidative stress

Identifiers

PMID27998022
PMCPMC5264131
OpenAlexW2565232424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.